BioPharmSignal logoBioPharmSignal

Biotech News

Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders

Jaguar Health (JAGX)Jaguar HealthFDA / regulatory

SAN FRANCISCO, CA / ACCESS Newswire / November 6, 2026 / Jaguar Health, Inc. ( NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's November 6, 2026 Special Meeting of Stockholders (the "Special Meeting"). Six proposals were submitted to and approved by the

Related news

JAGXJaguar Health2026-04-20 20:15 EST

Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders

JAGXJaguar Health2026-06-08 20:15 EST

Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders

IBRXImmunityBio2026-10-14 20:18 EST

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

HROWHarrow, Inc.2026-08-06 11:00 EST

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

IBRXImmunityBio2026-03-20 17:08 EST

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

HROWHarrow, Inc.2026-10-05 11:00 EST

Harrow Closes Acquisition of TYRVAYA®

SCYXSCYNEXIS2026-01-21 13:00 EST

SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247

SCYXSCYNEXIS2026-01-28 13:00 EST

SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

ALZNAlzamend Neuro2026-08-20 12:00 EST

Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC

View all latest news

Jaguar Health

Plant-Derived Gastrointestinal Medicines Jaguar Health develops prescription medicines derived from plants for serious gastrointestinal disorders. Its Napo subsidiaries lead development and commercialization of crofelemer for rare intestinal-failure conditions. Crofelemer Mechanism Crofelemer is a plant-derived antisecretory medicine...

Recent company news

JAGXJaguar Health2026-11-06 21:15 EST

Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders

JAGXJaguar Health2026-11-02 14:00 EST

CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)

JAGXJaguar Health2026-10-21 13:00 EST

Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder

JAGXJaguar Health2026-10-14 20:15 EST

Jaguar Health Provides Update Regarding Special Stock Dividend

JAGXJaguar Health2026-10-14 13:00 EST

Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer

Stock data

Close
0.41 USD
Market cap
2.12M USD
Exchange
NASDAQ
Sector
Biopharma
Location
San Francisco, California